Tag Archives: Duchenne Muscular Dystrophy

Lessons from Biotech: Tweaking the Imperfections

An increasing number of small biotech companies are being hatched to focus on a single disease or condition. The strategy goes against the diversified portfolio approach most big pharma companies have embraced, and instead puts all the eggs in one basket. Dart Therapeutics—one such company—has taken on Duchenne Muscular Dystrophy (DMD), a disease found in […]
Posted in Biotech, Orphan Drugs, R&D, Strategy | Also tagged , , , , , , | Leave a comment

The List So Far: FDA Breakthrough Designations

With announcements pouring in since the beginning of this year, FDA’s fourth and newest expedited approval pathway for medicines has begun to bear fruit. Established in 2012 within the FDA Safety and Innovation Act (FDASIA), Breakthrough Therapy designations have so far totaled 25 as of the end of July. With a separate senior management team […]
Posted in Biotech, FDA, Orphan Drugs, Regulatory | Also tagged , , , , , , , , , , , | Leave a comment
  • Categories

  • Meta